

**Table S1. Number of the Differentially Expressed Genes of Each In Vitro Model and Their Enriched Gene Ontology Categories, Related to Figure 1**

**Upregulated genes**

in vitro model	# Upregulated genes	Top GO of upregulated genes	# gene in GO <sup>a</sup>	p-value*
TNF $\alpha$	1307	immune response	111	9.8E-29
		defense response	75	6.4E-10
Dex	547	response to peptide hormone stimulus	16	1.8E-04
		positive regulation of programmed cell death	24	1.0E-03
High Ins	719	sterol biosynthetic process	19	1.2E-15
		lipid biosynthetic process	46	5.6E-14
Hypoxia	786	transcription	143	4.5E-14
		glycolysis	16	5.3E-08
Cotreatment	3065	immune response	153	1.6E-20
		translation	115	5.1E-19

**Downregulated genes**

in vitro model	# Downregulated genes	Top GO of downregulated genes	# gene in GO <sup>a</sup>	p-value*
TNF $\alpha$	1388	fatty acid metabolic process	39	1.5E-06
		negative regulation of biosynthetic process	64	1.1E-05
Dex	486	NA		
High Ins	924	translation	40	3.6E-05
		transcription	122	1.8E-03
Hypoxia	1158	oxidation reduction	81	8.4E-08
		fatty acid metabolic process	36	1.1E-07
Cotreatment	2974	oxidation reduction	183	3.1E-15
		coenzyme metabolic process	56	2.0E-9

Only the top two categories were shown.

a: It represents the number of upregulated or downregulated genes which are included in the particular GO category.

\*P-values were calculated by Fisher-Exact tests assessing the significance of over-representation. Multiple hypothesis testings were corrected by Benjamini-Hochberg correction.

**Table S2. Diet-Induced Obese Mouse Adipose Tissue Expression Data Sets Used in This Study, Related to Figures 2 and 3**

DIO mouse dataset	High-fat diet*	Duration of high-fat feeding	Method	Accession No.
WAT1	60%	12 weeks	Microarray	GSE14363
WAT2	30%	24 weeks	Microarray	GSM498652
WAT3	45%	13 weeks	Microarray	GSE28440

\* indicate the percent of calories from fat

**Table S3. Adipogenesis Data Sets Used in This Study, Related to Figures 2 and 3**

Adipogenesis dataset	Abbreviation	Method	Accession No.
3T3-L1 preadipocyte differentiation in vitro	Adipogenesis1	Microarray	GSE20696
3T3-L1 preadipocyte differentiation in vitro	Adipogenesis2	Microarray	GSE14004
Primary preadipocyte differentiated in vitro	Adipogenesis3	RNA-Seq	GSE29899

**Table S4. Results from Gene Set Enrichment Analysis Based on Genome-wide Data and the 1,319 Adipogenesis-Related Genes, Related to Figure 3**

See Excel file

**Table S5. DNA Sequence Motif Analysis of Regions that Gain DNase Hypersensitivity after the Different Insulin Resistance Treatments, Related to Figure 4**

<b>TNF<math>\alpha</math></b>		
Motif	P-value	CV error
<b>Bach,FRA1</b>	<b>6.6E-135</b>	<b>0.28</b>
<b>CREB</b>	<b>3.4E-109</b>	<b>0.37</b>
<b>NF-kappaB</b>	<b>2.6E-102</b>	<b>0.33</b>
<b>C/EBP</b>	<b>3.0E-102</b>	<b>0.37</b>
Tax/CREB	3.0E-93	0.40
<b>Nrf-2</b>	<b>8.2E-86</b>	<b>0.33</b>
RORA	7.8E-67	0.41
TEF-1	1.8E-55	0.41
Ik-1	4.7E-46	0.40
DEAF1	2.1E-31	0.42
<b>Hypoxia</b>		
Motif	P-value	CV error
<b>Bach</b>	<b>3.9E-210</b>	<b>0.28</b>
<b>Nrf-2</b>	<b>4.7E-111</b>	<b>0.33</b>
<b>Tax/CREB</b>	<b>4.1E-84</b>	<b>0.36</b>
<b>RORA</b>	<b>8.6E-70</b>	<b>0.38</b>
<b>CREB</b>	<b>1.5E-59</b>	<b>0.37</b>
PPARG	2.5E-42	0.45
Myc	4.9E-38	0.42
Arnt/Hif	1.7E-33	0.42
ER	5.3E-24	0.41
Pax	7.0E-24	0.43
<b>Dexamethasone</b>		
Motif	P-value	CV error
<b>GR</b>	<b>9.81E-186</b>	<b>0.33</b>
<b>Arnt/Hif</b>	<b>7.46E-109</b>	<b>0.39</b>
<b>Bach</b>	<b>8.16E-104</b>	<b>0.37</b>
Nrf-2	8.56E-54	0.41
<b>Myc</b>	<b>9.06E-40</b>	<b>0.38</b>
VDR:RXR	4.35E-37	0.41
C/EBP	1.23E-32	0.40
CREB	1.72E-28	0.43
TEF	4.44E-28	0.40
NF-1	1.66E-24	0.45
<b>High Insulin</b>		

Motif	P-value	CV error
E2F	5.7E-24	0.44
NF-1	4.5E-22	0.42
AP-2alpha	3.1E-14	0.46
Zfx	1.8E-12	0.46
Whn, AhR	2.2E-10	0.45
Arnt/Hif	2.9E-10	0.45
MIZF	1.4E-08	0.44
CNOT3	4.8E-08	0.46
PEA3	4.9E-08	0.47
Olf-1	2.0E-07	0.46

Motifs highlighted in bold are those with a cross-validation error (CV error) < 0.4.

**Table S6. DNA Sequence Motif Analysis of Regions that Lose DNase Hypersensitivity after the Different Insulin Resistance Treatments, Related to Figure 4**

<b>TNF<math>\alpha</math></b>		
Motif	P-value	CV error
MyoD,TCF3	2.3E-95	0.40
<b>NF-1</b>	<b>3.6E-90</b>	<b>0.39</b>
Arnt/Hif	1.9E-69	0.43
E2F	2.4E-52	0.40
Myc	5.7E-41	0.43
<b>Tal-1</b>	<b>5.7E-31</b>	<b>0.39</b>
TGIF	3.6E-27	0.44
AP-4	2.1E-26	0.45
XBP-1	6.4E-25	0.44
PPAR	1.1E-22	0.44
<b>Hypoxia</b>		
Motif	P-value	CV error
XBP1	1.9E-29	0.43
Myc	8.7E-28	0.41
NRF1	6.1E-20	0.42
MyoD,TCF3	5.7E-15	0.42
AP-4	6.0E-14	0.43
AhR, Arnt, HIF-1	7.9E-11	0.43
TCF3	1.1E-08	0.44
TTF1	1.0E-07	0.44
MTF1	4.8E-06	0.45
P53	1.3E-05	0.46
<b>Dexamethasone</b>		
Motif	P-value	CV error
NF-1	1.2E-75	0.42
MyoD,TCF3	2.9E-46	0.41
HEN1	2.7E-24	0.43
Elk-1	1.0E-20	0.45
Tal-1	3.6E-20	0.42
Nanog	2.8E-19	0.45
AP-4	5.6E-18	0.44
AP-2alphaA	4.2E-17	0.46
E2F	1.8E-16	0.43
Ikzf1	3.1E-15	0.45

<b>High Insulin</b>		
Motif	P-value	CV error
<b>Nrf-2</b>	<b>4.2E-79</b>	<b>0.37</b>
E2F	6.1E-65	0.42
Myc	3.7E-48	0.40
<b>Arnt/Hif</b>	<b>1.9E-45</b>	<b>0.38</b>
RORA	1.2E-44	0.40
<b>Bach</b>	<b>3.8E-43</b>	<b>0.34</b>
Tax/CREB	3.4E-40	0.41
XBP-1	8.2E-35	0.40
C/EBP	1.1E-33	0.41
ATF6	1.6E-32	0.42

Motifs highlighted in bold are those with a cross-validation error (CV error) < 0.4.



**Table S7. DNA Sequence Motif Analysis of Enriched Regions Identified from p65 ChIP-Seq Experiment, Related to Figure 4**

Motif Name	P value	CV error
<b>NF-kappaB</b>	<b>2.94E-164</b>	<b>0.27</b>
<b>C/EBP</b>	<b>8.06E-53</b>	<b>0.37</b>
PARP	8.26E-43	0.43
TEF-1	3.50E-27	0.43
RBP-Jkappa	2.42E-19	0.44
GABP	2.92E-19	0.42
E2F	1.34E-18	0.41
Olf-1	1.79E-18	0.43
Helios A	8.32E-16	0.42
MAF	5.53E-15	0.45
HSF	7.14E-14	0.45
MIZF	2.09E-13	0.42
STAT	1.82E-11	0.44
EBF	2.24E-10	0.43

Motifs highlighted in bold are those with a cross-validation error (CV error) < 0.4.

**Table S8. Primers Used in the Current Study, Related to Figures 1, 3, and 5**

qPCR primers

Adipoq	TGGAATGACAGGAGCTGAAGG GCGAATGGGTACATTGGGAAC
Fasn	GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCAG
Pparg	TCGCTGATGCACTGCCTATG GAGAGGTCCACAGAGCTGATT
Glut4	GTGACTGGAACACTGGTCCTA CCAGCCACGTTGCATTGTAG
Glut1	CAGTTCGGCTATAAACTGGTG GCCCCGACAGAGAAGATG
Cebpa	CCCACTCAGCTTACAACAGG GCTGGCGACATACAGTACAC
Cebpb	ACACGTGTAAGTGCAGCCG GCTCGAAACGGAAAAGGTTC
Rps27	CCTTCATCCCTCTCCAGAAGA CCGTGGTGATTTTATAGCATCTC
Ccl2	TTAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT
Ccl5	GCTGCTTTGCCTACCTCTCC TCGAGTGACAAACACGACTGC
Ccl9	GCTGCTTTGCCTACCTCTCC TCGAGTGACAAACACGACTGC
Tnf	CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG
Il6	TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
Mmp2	CAAGTTCCCCGGCGATGTC TTCTGGTCAAGGTCACCTGTC

ChIP-PCR primers

Lcn2	GCGGGGTAGTCCATCCTTTACCA CCCTGTGCCTGCCAGAATCCAA
Socs3	AGAAACATAAACTCCCGTCT CCCATAAGCACAGATCAGC
Irf2	TCTGCCCACCTCTTACCAC CCAATGCCCCATGAGTCG
Glut1	ACAGCCCGTCATTGCAAG CCTACTGTGCCCGTCCA

III5	ATCGCCTCAAAGCTTGGTC
	CGGCCAATAACATTGAGTCAC
Alb	CAATGAAATGCGAGGTAAGTATGG
	TCTTTAACCAATAACTGTAGATCATTA